GRANDPHARMA News

GRANDPHARMA: Notice of availability to Registered Shareholders and Reply Form

Apr 26 10:33 ET

GRANDPHARMA: Notice of availability to Non-registered Shareholders and Reply Form

Apr 26 10:32 ET

GRANDPHARMA: ESG Report 2023

Apr 26 10:32 ET

GRANDPHARMA: Proxy form for the annual general meeting to be held on Tuesday, 4 June 2024 or any adjournment thereof

Apr 26 10:31 ET

GRANDPHARMA: Notice of Annual General Meeting

Apr 26 10:31 ET

GRANDPHARMA: (1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR SERVING MORE THAN NINE YEARS; AND (3) NOTICE OF ANNUAL GENERAL MEETING

Apr 26 10:30 ET

GRANDPHARMA: Annual Report 2023

Apr 26 10:30 ET

GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024

Apr 3 07:42 ET

GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES A GLOBAL INNOVATIVE PRODUCT FOR THE TREATMENT OF DEMODEX BLEPHARITIS AND MEIBOMIAN GLAND DISEASE WITH DEMODEX MITES

Mar 27 05:20 ET

GRANDPHARMA: Final dividend for the year ended 31 December 2023

Mar 27 05:19 ET

GRANDPHARMA: Final dividend for the year ended 31 December 2023

Mar 26 06:03 ET

GRANDPHARMA: THE GLOBAL INNOVATIVE RDC DRUG OF THE GROUP ITM-11 IS APPROVED TO CONDUCT PHASE III CLINICAL STUDY IN CHINA

Mar 24 06:13 ET

GRANDPHARMA: Final dividend for the year ended 31 December 2023

Mar 21 07:45 ET

GRANDPHARMA: Clarification Announcement in relation to Closure of Register of Members

Mar 21 07:44 ET

GRANDPHARMA: Final dividend for the year ended 31 December 2023

Mar 19 18:02 ET

GRANDPHARMA: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

Mar 19 18:01 ET

GRANDPHARMA: DATE OF BOARD MEETING

Mar 7 04:40 ET

GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 WAS APPROVED TO CONDUCT PHASE I CLINICAL STUDY IN CHINA

Mar 7 04:36 ET

GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE NDA OF A GLOBAL INNOVATIVE HORMONE NANOSUSPENSION EYE DROPS WAS APPROVED BY THE FDA

Mar 7 04:33 ET

GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024

Mar 4 04:30 ET